Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neumifil - Pneumagen

Drug Profile

Neumifil - Pneumagen

Alternative Names: NeumifilTM

Latest Information Update: 30 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pneumagen
  • Class Anti-infectives; Antivirals; Proteins
  • Mechanism of Action Epithelial cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections; Respiratory syncytial virus infections; Respiratory tract infections
  • Research COVID 2019 infections

Most Recent Events

  • 27 May 2020 Pneumagen plans a clinical trial for COVID-19 infections (Prevention, Treatment) in first half of 2021
  • 28 Apr 2020 Pharmacodynamics data from three in vitro studies in COVID-2019 infections released by Pneumagen
  • 28 Apr 2020 Pneumagen plans clinical development in COVID-2019 infections (Prevention, Treatment)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top